GlassScriptPhysician profile
Karin Anderson
NPI 1871862359
$8,175.33
in general payments reported to CMS, 2019-2025
24 companies · $1,834 in 2025
The $1,834 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $590 · 2022: $1,288 · 2023: $2,317 · 2024: $2,145 · 2025: $1,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,297.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,696.43 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $2,331.74 | 2021-2025 | Descovy, Biktarvy |
| Lilly USA, LLC | $592.85 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Janssen Products, LP | $340.36 | 2021-2022 | |
| Abbvie INC. | $327.38 | 2022-2025 | |
| Napo Pharmaceuticals INC | $307.76 | 2023-2025 | Mytesi |
| Merck Sharp & Dohme LLC | $283.60 | 2022-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $198.32 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $143.26 | 2024-2025 | Trogarzo, Egrifta |
| Novo Nordisk INC | $135.57 | 2022-2024 | Wegovy, Ozempic |
| Exact Sciences Corporation | $120.98 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.07 | 2025 | Caplyta |
| Emd Serono, INC. | $85.24 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.81 | 2023-2025 | Xifaxan |
| Organon LLC | $78.25 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $71.93 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $56.96 | 2022 | |
| Axsome Therapeutics, INC. | $54.11 | 2024-2025 | Auvelity |
| Verity Pharmaceuticals INC. | $47.18 | 2025 | Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.45 | 2023 | Synjardy, Tradjenta, Jardiance |
| Antares Pharma, INC. | $23.18 | 2023 | Tlando, Xyosted, Nocdurna |
| Corcept Therapeutics | $22.65 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $19.27 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $16.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.